Calgary, Alberta--(Newsfile Corp. - October 10, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today shared promising results from a recent study on MB204. The research was conducted by Drs. Julie Le Merrer and Jerome Becker of the iBraiN Institute in Tours, France, to investigate the impact of MB204 in the... Read More